EX-10.10 2 d942137dex1010.htm EX-10.10 [*] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of...Collaboration and Exclusive License Agreement • May 5th, 2020 • Delaware
This COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT (the “Agreement”), effective as of March 10 , 2014 (the “Effective Date”), is made by and between (i) AnaptysBio, Inc., a Delaware corporation, having a place of business at 10421 Pacific Center Court, Suite 200, San Diego, California 92121 (“AnaptysBio”), and (ii) TESARO, Inc., a Delaware corporation, having a place of business at 1000 Winter Street, Suite 3300, Waltham, Massachusetts 02541 (“TESARO US”) and TESARO Development, Ltd., a Bermuda corporation, having its principal office at Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda (together with TESARO US, “TESARO”).
COLLABORATION AND EXCLUSIVE LICENSE AGREEMENTCollaboration and Exclusive License Agreement • November 5th, 2009 • Transgenomic Inc • Laboratory analytical instruments • Nebraska
This Collaboration and Exclusive License Agreement, dated as of January 23, 2009 (this “Agreement”), is entered into between Transgenomic, Inc., a Delaware corporation (“Transgenomic”), and Power3 Medical Products, Inc., a New York corporation (“Power3”).
CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. COLLABORATION AND EXCLUSIVE...Collaboration and Exclusive License Agreement • June 23rd, 2014 • Ambrx Inc • Pharmaceutical preparations • New York
THIS COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT (ADC) (the “Agreement”) is made and entered into effective as of May 2, 2013 (the “Effective Date”) by and between AMBRX, INC., a Delaware corporation having its principal place of business at 10975 North Torrey Pines Road, La Jolla, CA 92037 (“Ambrx”) and BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation headquartered at 345 Park Avenue, New York, New York 10154 (“BMS”). Ambrx and BMS are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
AMENDMENTCollaboration and Exclusive License Agreement • October 17th, 2017 • Ablynx NV • Biological products, (no disgnostic substances)
This amendment (”Amendment”), executed on July 20, 2015, is an amendment to the RESEARCH COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT with an effective date of January 31, 2014 (“Agreement”) entered into by and between MERCK SHARP & DOHME CORP., a corporation organized and existing under the laws of New Jersey (“Merck”) and ABLYNX N.V., a limited liability company organized and existing under the laws of Belgium (“Ablynx”) registered with the legal entities register under number BE 0475295446 (district of Ghent) and whose registered office is situated at Technologiepark 21, 9052 Zwijnaarde, Belgium.
COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT by and between MERCK SHARP & DOHME CORP. and CHIMERIX, INC.Collaboration and Exclusive License Agreement • March 8th, 2013 • Chimerix Inc • Pharmaceutical preparations • New York
THIS COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT (“Agreement”), effective as of July 23, 2012 (the “Effective Date”), is made by and between MERCK SHARP & DOHME CORP., a corporation organized and existing under the laws of New Jersey, (“Merck”) and CHIMERIX, INC., a corporation organized and existing under the laws of the State of Delaware (“Chimerix”).
AMENDMENT NO. 1 TO COLLABORATION AND EXCLUSIVE LICENSE AGREEMENTCollaboration and Exclusive License Agreement • February 25th, 2015 • TESARO, Inc. • Pharmaceutical preparations
This Amendment No. 1 to the Collaboration and Exclusive License Agreement (this “Amendment”) effective as of November 28, 2014 (the “Amendment Date”), is entered into is made by and between (i) AnaptysBio, Inc., a Delaware corporation, having a place of business at 10421 Pacific Center Court, Suite 200, San Diego, California 92121 (“AnaptysBio”), and (ii) TESARO, Inc., a Delaware corporation, having a place of business at 1000 Winter Street, Suite 3300, Waltham, Massachusetts 02541 (“TESARO US”) and TESARO Development, Ltd., a Bermuda corporation, having its principal office at Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda (together with TESARO US, “TESARO”).
AMENDMENT NO. 3 TO COLLABORATION AND EXCLUSIVE LICENSE AGREEMENTCollaboration and Exclusive License Agreement • February 25th, 2021 • Anaptysbio, Inc • Pharmaceutical preparations
This Amendment No. 3 to the Collaboration and Exclusive License Agreement (this “Amendment”) effective as of October 23, 2020 (the “Amendment Date”), is entered into is made by and between (i) AnaptysBio, Inc., a Delaware corporation, having a place of business at 10421 Pacific Center Court, Suite 200, San Diego, California 92121 (“AnaptysBio”), and (ii) TESARO, Inc., a Delaware corporation, having a place of business at 1000 Winter Street, Suite 3300, Waltham, Massachusetts 02541 (“TESARO US”) and TESARO Development, Ltd., a Bermuda corporation, having its principal office at Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda (together with TESARO US, “TESARO Collectively, AnaptysBio and TESARO are referred to as the “Parties” and, individually, as a “Party”.
AMENDMENT NO. 4 TO COLLABORATION AND EXCLUSIVE LICENSE AGREEMENTCollaboration and Exclusive License Agreement • March 7th, 2022 • Anaptysbio, Inc • Pharmaceutical preparations
This Amendment No. 4 to the Collaboration and Exclusive License Agreement (this “Amendment”) effective as of October 21, 2021 (the “Amendment Date”), is entered into by and between (i) AnaptysBio, Inc., a Delaware corporation, having a place of business at 10770 Wateridge Circle, Suite 210, San Diego, California 92121 (“AnaptysBio”), and (ii) TESARO, Inc., a Delaware corporation, having a place of business at 1000 Winter Street, Suite 3300, Waltham, Massachusetts 02541 (“TESARO US”) and TESARO Development, Ltd., a Bermuda corporation, having its principal office at Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda (together with TESARO US, “TESARO”). Collectively, AnaptysBio and TESARO are referred to as the “Parties” and, individually, as a “Party”.
AMENDMENT NO. 2 TO COLLABORATION AND EXCLUSIVE LICENSE AGREEMENTCollaboration and Exclusive License Agreement • May 6th, 2016 • TESARO, Inc. • Pharmaceutical preparations
This Amendment No. 2 to the Collaboration and Exclusive License Agreement (this “Amendment”) effective as of February 29, 2016 (the “Amendment Date”), is entered into is made by and between (i) AnaptysBio, Inc., a Delaware corporation, having a place of business at 10421 Pacific Center Court, Suite 200, San Diego, California 92121 (“AnaptysBio”), and (ii) TESARO, Inc., a Delaware corporation, having a place of business at 1000 Winter Street, Suite 3300, Waltham, Massachusetts 02541 (“TESARO US”) and TESARO Development, Ltd., a Bermuda corporation, having its principal office at Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda (together with TESARO US, “TESARO”).
COLLABORATION AND EXCLUSIVE LICENSE AGREEMENTCollaboration and Exclusive License Agreement • August 12th, 2024 • Adaptimmune Therapeutics PLC • Biological products, (no disgnostic substances) • England and Wales
This Collaboration and Exclusive License Agreement (“Agreement”) is effective as of 30 May 2024 (“Effective Date”) made by and between Adaptimmune Limited, having offices at 60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RX, UK (“Adaptimmune”), and Galapagos NV, having offices at Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium (“Galapagos”). Each of Galapagos and Adaptimmune may be referred to in this Agreement individually as a “Party” or together as the “Parties.”
COLLABORATION AND EXCLUSIVE LICENSE AGREEMENTCollaboration and Exclusive License Agreement • May 28th, 2021 • Ambrx Biopharma Inc. • Biological products, (no disgnostic substances) • New York
THIS COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is made and entered into effective as of March 4, 2019 (the “Effective Date”) by and between AMBRX, INC., a Delaware corporation having its principal place of business at 10975 North Torrey Pines Road, La Jolla, CA 92037 (“Ambrx”), and BeiGene, Ltd., a corporation organized under the laws of the Cayman Islands having an address at c/o Mourant Ozannes Corporate Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman KY1-1108, Cayman Islands (“BeiGene”). Ambrx and BeiGene are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
COLLABORATION AND EXCLUSIVE LICENSE AGREEMENTCollaboration and Exclusive License Agreement • May 10th, 2021 • Novavax Inc • Biological products, (no disgnostic substances)
COLLABORATION AND EXCLUSIVE LICENSE AGREEMENTCollaboration and Exclusive License Agreement • August 7th, 2008 • Amag Pharmaceuticals Inc. • In vitro & in vivo diagnostic substances • New York
[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
COLLABORATION AND EXCLUSIVE LICENSE AGREEMENTCollaboration and Exclusive License Agreement • May 2nd, 2014 • TESARO, Inc. • Pharmaceutical preparations • Delaware
This COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT (the “Agreement”), effective as of March 10, 2014 (the “Effective Date”), is made by and between (i) AnaptysBio, Inc., a Delaware corporation, having a place of business at 10421 Pacific Center Court, Suite 200, San Diego, California 92121 (“AnaptysBio”), and (ii) TESARO, Inc., a Delaware corporation, having a place of business at 1000 Winter Street, Suite 3300, Waltham, Massachusetts 02541 (“TESARO US”) and TESARO Development, Ltd., a Bermuda corporation, having its principal office at Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda (together with TESARO US, “TESARO”).
